Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Source: 
Forbes
snippet: 

Nektar Pharmaceuticals and Bristol-Myers Squibb announced results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer.